The online version of this article (doi:10.1186/1756-8722-7-25) contains supplementary material, which is available to authorized users.
The authors declare no conflict of interests.
KS performed the research and wrote the manuscript; WZ, YC, and WTH performed the research; PY and ZJZ designed the research and wrote the manuscript. All authors read and approved the manuscript.
Myeloproliferative neoplasms (MPNs) are blood malignancies manifested in increased production of red blood cells, white blood cells, and/or platelets. A major molecular lesion associated with the diseases is JAK2V617F, an activation mutation form of tyrosine kinase JAK2. Cardiovascular events represent the leading cause of morbidity and mortality associated MPNs, but the underlying mechanism is not well understood.
Previously, we generated JAK2V617F transgenic mice which displayed MPN-like phenotypes. In the present study, we further characterized these mice by analyzing the time course of MPN phenotype development and associated cardiac abnormalities. We performed detailed histochemical staining of cardiac sections.
JAK2V617F transgenic mice developed cardiomegaly as a subsequent event of increased blood cell production during the course of MPN phenotype development. The cardiomegaly is manifested in increased ventricular wall thickness and enlarged cardiomyocytes. Trichrome and reticulin staining revealed extensive collagen fibrosis in the heart of JAK2V617F transgenic mice. Thrombosis in the coronary artery and inflammatory cell infiltration into cardiac muscle were also observed in JAK2V617F transgenic mice, and the latter event was accompanied by fibrosis.
JAK2V617F-induced blood disorders have a major impact on heart function and lead to cardiac hypertrophy. JAK2V617F transgenic mice represent an excellent model system to study both hematological malignancies and cardiovascular diseases.
Authors’ original file for figure 113045_2014_390_MOESM1_ESM.tiff
Authors’ original file for figure 213045_2014_390_MOESM2_ESM.tiff
Authors’ original file for figure 313045_2014_390_MOESM3_ESM.tiff
Authors’ original file for figure 413045_2014_390_MOESM4_ESM.tiff
Authors’ original file for figure 513045_2014_390_MOESM5_ESM.tiff
Authors’ original file for figure 613045_2014_390_MOESM6_ESM.tiff
Authors’ original file for figure 713045_2014_390_MOESM7_ESM.tiff
Authors’ original file for figure 813045_2014_390_MOESM8_ESM.tiff
Kvasnicka HM, Thiele J: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010, 85: 62-69. PubMed
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007, 110: 1092-1097. 10.1182/blood-2007-04-083501. CrossRefPubMed
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061. 10.1016/S0140-6736(05)71142-9. CrossRefPubMed
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023. CrossRefPubMed
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148. 10.1038/nature03546. CrossRefPubMed
Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM: Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998, 91: 419-430. PubMed
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010, 363: 1117-1127. 10.1056/NEJMoa1002028. CrossRefPubMed
Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O’Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013, 6: 81-10.1186/1756-8722-6-81. PubMedCentralCrossRefPubMed
Hoff J: Methods of blood collection in the mouse. Lab Anim. 2000, 29: 47-53.
- Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
Wanting Tina Ho
Zhizhuang Joe Zhao
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II